Curevo Vaccine

Eli Lilly and Company has acquired Curevo Vaccine, a biotech company developing a next-generation shingles vaccine that incorporates the Access to Advanced Health Institute’s (AAHI) proprietary SLA-SE adjuvant technology.

Summary of transaction details:

• Value: Not Disclosed
• Sector: Healthcare & Biotech
• Advisor: Not Disclosed
• Key Entities: Eli Lilly and Company, Curevo Vaccine, Access to Advanced Health Institute (AAHI)
• Location: United States

Note: This acquisition highlights the growing importance of next-generation adjuvants in vaccine development and is expected to have a significant impact on the healthcare and biotech industry.